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Abstract
Background: Understanding whether schistosomiasis control programmes are on course to control morbidity
and potentially switch towards elimination interventions would benefit from user-friendly quantitative tools that
facilitate analysis of progress and highlight areas not responding to treatment. This study aimed to develop and
evaluate such a tool using large datasets collected during Schistosomiasis Control Initiative-supported control
programmes.
Methods: A discrete-time Markov model was developed using transition probability matrices parameterized with
control programme longitudinal data on Schistosoma mansoni obtained from Uganda and Mali. Four matrix variants
(A-D) were used to compare different data types for parameterization: A-C from Uganda and D from Mali. Matrix A
used data at baseline and year 1 of the control programme; B used year 1 and year 2; C used baseline and year 1
from selected districts, and D used baseline and year 1 Mali data. Model predictions were tested against 3 subsets
of the Uganda dataset: dataset 1, the full 4-year longitudinal cohort; dataset 2, from districts not used to
parameterize matrix C; dataset 3, cross-sectional data, and dataset 4, from Mali as an independent dataset.
Results: The model parameterized using matrices A, B and D predicted similar infection dynamics (overall and
when stratified by infection intensity). Matrices A-D successfully predicted prevalence in each follow-up year for low
and high intensity categories in dataset 1 followed by dataset 2. Matrices A, B and D yielded similar and close
matches to dataset 1 with marginal discrepancies when comparing model outputs against datasets 2 and 3. Matrix
C produced more variable results, correctly estimating fewer data points.
Conclusion: Model outputs closely matched observed values and were a useful predictor of the infection dynamics
of S. mansoni when using longitudinal and cross-sectional data from Uganda. This also held when the model was
tested with data from Mali. This was most apparent when modelling overall infection and in low and high infection
intensity areas. Our results indicate the applicability of this Markov model approach as countries aim at reaching
their control targets and potentially move towards the elimination of schistosomiasis.
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Background
In recent years there has been a renewed focus on the
control and possible elimination of certain neglected trop-
ical diseases (NTDs) by the global health community. One
of the NTDs with the greatest human health and socio-
economic burden is schistosomiasis, estimated to infect
over 238 million people [1] at a global cost of 3.3–4.5
million disability-adjusted life years (DALYs). Approxi-
mately 85 % of people infected with schistosomes reside
in sub-Saharan Africa (SSA), with the disease potentially
causing over 200,000 deaths per year [2, 3]. National-scale
control programmes are now in place in many countries,
using preventive chemotherapy (PC) by mass drug admin-
istration (MDA) with praziquantel (PZQ) [4].
The pharmaceutical company Merck KGaA has
donated over 290 million tablets of PZQ to the World
Health Organization (WHO) and has committed up to a
further 250 million tablets per year from 2016 [5]. The
tablets are distributed by the Ministries of Health of en-
demic countries, where in some, non-governmental
organizations such as the Schistosomiasis Control Initia-
tive (SCI) provide technical support and assistance (and
in some cases purchasing and supplying additional PZQ)
to these programmes [6, 7]. Since its establishment in
2002, SCI has helped to provide over 140 million treat-
ments for schistosomiasis to at-risk children and adults
in SSA and the Middle East [8]. As part of the monitor-
ing and evaluation (M&E) component that runs along-
side the treatment campaigns, SCI has contributed to
the collection of rich longitudinal datasets from numer-
ous countries on the impact of treatment on prevalence,
intensity and morbidity. Many schistosomiasis control
programmes have been running for several years, and
have achieved their primary target of controlling
schistosomiasis-related morbidity (where the aim of “con-
trol” is reducing prevalence of heavy infection to < 5 %
across sentinel sites at 75 % national coverage [9]),
whether from intestinal schistosomiasis (caused predom-
inantly by Schistosoma mansoni) or from urogenital schis-
tosomiasis (caused predominantly by S. haematobium)
[10]. With this in mind, the WHO, alongside its global
partners, has set the agenda for the next stage of control.
The London Declaration on NTDs in January 2012 en-
dorsed the ambitious targets set by the WHO for the
control and elimination of many NTDs, including schisto-
somiasis, with the elimination ‘as a public health problem’
from most WHO regions and by selected African
countries by 2020 (i.e. reducing prevalence of heavy
infection < 1 % in all sentinel sites) [9, 11, 12]. In
some local settings, interruption of transmission is
also anticipated, thereby accelerating elimination of
the disease [12].
The impact of a control programme is often measured
by changes in the prevalence and/or the intensity of
infection. Preventive chemotherapy by MDA with PZQ
has been demonstrated to be, in general, highly effective
in reducing both the prevalence and intensity of schisto-
some infection [13–15]. The development of a user--
friendly quantitative tool that uses these impact
measurements to inform programme managers as to
whether their programme is on target to meet their
goals would be invaluable in assisting with programme
design and evaluation and in providing an early warning
of potential transmission ‘hotspots’ or poor programme
performance.
A Markov statistical model was developed to capture
soil-transmitted helminth (STH) infection dynamics
through rounds of MDA (with benzimidazoles), by
Montresor and colleagues in 2013 [16, 17]. The authors
demonstrated that their model successfully predicted
changes in the prevalence of Ascaris lumbricoides,
Trichuris trichiura and hookworm (consisting of the two
species that infect humans: Ancylostoma duodenale and
Necator americanus) through five rounds of MDA using
data collected at baseline and after one round of treat-
ment in Vietnam to parameterize the Markov Transition
Probability (MTP) matrix; the essential ingredient of
such Markov models. The predictive capability of the
model was also successfully validated against STH data
from 26 control programmes in 16 countries [17].
The main appeal of the Markov approach resides in its
simplicity [18], whereby the underlying transmission
dynamics are not modelled explicitly but are captured
empirically using a purely statistical approach based on
estimated transition probabilities (TP). The model can
be used to track progress and to identify deviations from
expected programme performance where observed
values fall outside of predicted uncertainty intervals (e.g.
95 % prediction intervals, PIs).
Here, for the first time, we extend the discrete-time
Markov model approach, in which both time and infec-
tion states (intensity groups) are defined, and apply it to
S. mansoni, a causative agent of intestinal schistosomia-
sis across Africa, South America, and the Yemen. We
test the model under contrasting control programme
scenarios, using unique and extensive datasets from
SCI-supported programmes in Uganda and Mali.
Our specific aims in this study were to: (i) develop and
test a discrete-time Markov model for schistosomiasis
using data on the intensity and prevalence of S. mansoni
infection during mass treatment with PZQ; (ii) introduce
measurements of precision around predictions in the
form of 95 % PIs; (iii) estimate changes in the overall
infection prevalence and the prevalence in infection in-
tensity categories over time; (iv) qualitatively compare
the predictive capabilities of the model parameterized
using MTP matrices estimated from different settings
within the same country (Uganda) and from a different
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country (Mali), to test the transferability of the TPs to
different regions; (v) test the robustness of the model’s
predictive capabilities using data from non-baseline
years to estimate the MTP matrices; and (vi) elucidate
the ability of different data types (longitudinal and cross-
sectional data) to qualitatively test the predictions of
each matrix.
Methods
Model development
The development of a Markov model for STH infection
has been explained fully elsewhere [16]. Briefly, in rela-
tion to S. mansoni, the proportion of individuals in each
of the 4 WHO-recommended infection classes defined
by estimates of eggs per gram (epg) of faeces (not
infected, 0 epg; infected at light intensity, 1–99 epg;
infected at moderate intensity, 100–399 epg; infected at
high intensity, ≥ 400 epg [19]) and referred to as “condi-
tional states” (CS), is calculated from pre-treatment
baseline data [20]. Subsequently, an individual’s prob-
ability of transition (if any) to other CS prior to the next
round of treatment (year 1) is calculated using the
observed change in the proportion of followed individ-
uals in each category (from baseline to year 1). These
observed changes are used to parameterize a MTP
matrix, formed from a set of 16 transition probabilities
(TPs), as illustrated in Fig. 1. The model is initialised
using observed baseline starting values. Then, through a
series of Markov processes defined by the MTP matrix
(see Additional file 1: Text S1 and Table S1), projections
are made on the proportion of infected individuals by in-
tensity class through rounds of MDA.
In the first instance, we focused on S. mansoni data
collected from Uganda between the inception of the
programme in 2003 and for the first 3 annual follow-up
rounds after baseline. For further details of the control
programme in Uganda see [21, 22]. As part of the na-
tional control programme, data were collected as egg
counts (expressed as the arithmetic mean epg) from a
cohort of 125 children (aged 6–13) per school, from 37
schools across the country, over a time span of 4 years.
For the calculation of the TPs from the full Uganda
dataset, longitudinal data between baseline and year 1
were used (i.e. only data from those individuals who
could be identified at each of those time points, namely
1,258 individuals). To quantify uncertainty around the
model projections (expanding on the previously pub-
lished version of the model applied to STH [15, 16]),
95 % prediction intervals (95 % PIs) associated with each
TP were calculated through bootstrap resampling (with
replacement) for 10,000 iterations, using the R package
‘boot’ version 1.3–9 [23–26]. The 95 % PIs were calcu-
lated in the following steps: 1) a new ‘dataset’ was gener-
ated through bootstrapping allowing for the calculation
of a new MTP matrix (set of 16 TPs); 2) the model was
run (using these TPs) to calculate the reduction in
Fig. 1 Transition diagram illustrating a Markov transition probability matrix [16]
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prevalence over time; 3) steps 1) and 2) were repeated
10,000 times; 4) for each time point, the predicted mean
prevalence was calculated; and 5) from the range of pre-
dicted prevalence levels generated, the 95 % PIs were
constructed using the 2.5 % and 97.5 % percentiles. Ini-
tially, for the observed data, the full cohort of individuals
who were followed up from baseline to year 3 of the
intervention was included (757 individuals). Since some
of the individuals in this dataset were also used for the
calculation of the TPs (as would be the case in practice
when using these models), it was expected that the pre-
dicted prevalence at year 1 would follow the observed
values from the full dataset 1 (Table 1) very closely. In
order to test the transferability of the model using inde-
pendent data, the TPs calculated from the full Uganda
dataset were also used to test model predictions against
longitudinal data from Mali. Conversely, to further test
the robustness of the model, longitudinal baseline and
year 1 data from Mali was also used to parameterize a
separate model and tested against observed Uganda lon-
gitudinal data. These additionally tested the flexibility of
the model to different starting baseline prevalence levels
(for Mali the baseline overall prevalence was 26.5 % for
S. mansoni infection whilst for Uganda the overall preva-
lence was 43.0 %).
Datasets used and models developed
The data were collected as part of a treatment campaign
in Uganda for school-aged children (SAC) from 2003 to
2006 and in Mali from 2004 to 2007 (Fig. 2). We
selected SCI data from Uganda as our primary dataset to
parameterize and validate our model because: (i) Uganda
was the first ‘SCI country’ to commence large-scale
control of schistosomiasis in 2003, and thus has the
most extensive longitudinal datasets (including pre-
intervention baseline); (ii) S. haematobium infections are
highly localised to specific regions within Uganda, with
prevalence mostly below 1 %, and hence the potentially
confounding impact of S. haematobium infection on the
transition probabilities can be assumed to be minimal
[27]; and (iii) Uganda has been very successful in imple-
menting control [13], making this country an ideal
candidate to move towards elimination of schistosomia-
sis as a public health problem. The extensive Ugandan
dataset also enabled the model to be tested against data
obtained from contrasting districts and disease endemic-
ities. Three districts were selected based on their
geographic spread and the distribution of infection in-
tensities: Moyo (only low intensity infections); Busia
(only low and moderate intensity infections); Masindi
(only moderate and high intensity infections). There
were no districts with only moderate or only high infec-
tion intensities. The remaining districts on which the
model was tested (i.e. dataset 2) contained a varied
composition of intensities (and were not used for the de-
velopment of matrix C) (see Fig. 2 and Additional file 1:
Table S2 for further details on the districts). The dataset
and its different subsets that were used to test the
predictive capabilities of the models are listed in Table 1.
Table 2 shows other MTP matrices that were developed
by the same method described in the previous sub-sec-
tion, Model development.
In summary, 4 matrix variants (A-D) were used to
compare different data types for parameterization: A-C
from Uganda and D from Mali. These were tested on 4
datasets (1–4): dataset 1 refers to the full longitudinal
cohort data from Uganda; dataset 2 to a subset of
dataset 1 using districts not used to parameterize matrix
C; dataset 3 to cross-sectional data from Uganda, and
dataset 4 comprises data from Mali, which acted as a
completely independent dataset. Matrix A was an ‘ideal’
scenario where longitudinal baseline and year 1 data
from a large programme were available to parameterize
the model and develop the TPs. The TPs were assumed
to be fixed throughout the years. In practice, since
changes between intensity groups are likely to be more
dramatic after the first treatment in a treatment-naïve
area, matrix B was developed using TPs from post-
Table 1 Data used for testing model/matrices
Observed baseline prevalence (%)
Dataset Data type Description Sample size (n) Overall
prevalence
Low
intensity
Moderate
intensity
High
intensity
1 Uganda longitudinal baseline
to year 3
Full longitudinal data set 747 43.0 16.6 11.4 15.0
2 Uganda longitudinal baseline
to year 3
4a Ugandan districts out of 7 400 46.5 15.5 12.3 18.8
3 Uganda cross-sectional baseline
to year 3
Varying sample size per year,
full programme data
Baseline: 4,222;
Year 1: 3,973;
Year 2: 4,192;
Year 3: 3,373
45.2 16.0 11.7 17.6
4 Mali longitudinal baseline
to year 2
Full longitudinal data set 897 26.5 12.5 7.1 6.9
aThese districts were selected for their wide range of infection intensities and NOT used to the development of matrix C
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baseline treatment, between year 1 and year 2. The use
of matrix C predictions on dataset 2 is an illustration of
a scenario where an ‘independent’ matrix might be used,
calculated from a smaller dataset, to estimate changes
on a ‘separate’ smaller dataset (dataset 2) that is not used
to develop the TPs. Matrix D illustrates a case where
longitudinal data from another country are used to
develop the TPs (Mali) in order to predict changes in
prevalence in a separate country (Uganda). In the follow-
ing sections we distinguish between ‘estimation’ (the
estimated TP values), ‘prediction’ (the model outputs),
95 % prediction intervals (95 % PIs, constructed as
described above) and 95 % confidence intervals (95 %
CIs) around the data (calculated as binomial proportion
confidence intervals). As a conservative approach to the
qualitative model assessment, we focus on the ability of
the models to capture the observed point prevalence
values within the 95 % PIs whilst also highlighting
whether the 95 % PIs of the model capture the 95 % CIs
of the observed data.
Matrix and dataset combinations
Matrix A, datasets 1, 2, 3, 4
Matrix A was calculated using all 1,245 individuals that
were followed from baseline to year one in the Uganda
dataset. Dataset 1 contains 747 of these individuals who
were followed for a further 3 years (lower numbers due
to loss of follow-up). Therefore, we expected Matrix A
to provide the most accurate predictions, on dataset 1.
In addition, to test how the model performed with
smaller sample sizes, less complete data, and other data
types, selected districts (dataset 2) and cross-sectional
data (dataset 3) were used. To test how well the model
performed using matrix A on a completely independent
dataset, longitudinal data from Mali (baseline to year 2;
dataset 4) were used.
Fig. 2 Map of Africa showing Mali (red) and Uganda (green). Subset: Uganda by district in study sample
Table 2 Markov transition probability (MTP) matrices developed
MTP
matrix
Country Number of
districts
Time points used
to develop matrix
Sample
size (n)
A Uganda 7 Baseline and year 1 1,245
B Uganda 7 Year 1 and year 2 1,260
C Uganda 3 Baseline and year 1 540
D Mali - Baseline and year 1 1,092
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Matrix B, datasets 1, 2, 3
It is important to understand how the model and its
outputs differ between 2 different time points within
the same settings, since the model explicitly assumes
that the TPs remain constant between each time
point. To explore this, instead of using the baseline
and year 1 data to calculate the TPs for the matrix,
data derived from follow-up years 1 and 2 were used
from the full Uganda dataset (matrix B). The outputs
from these TPs were compared to the observed values
from datasets 1–3.
Matrix C, datasets 1, 2, 3
A comparison was made between model outputs using
smaller sample sizes for situations in which fewer data
are available to parameterize TPs. This was achieved by
selecting district-level subsets of the data for calculating
TPs. The predictions were also tested against dataset 1
(longitudinal Uganda dataset) to represent a case where
limited data would be used for the development of the
TPs to project the expected impact of a much larger
programme. In addition, to test the least favourable data
scenario where there is very high loss to follow-up, the
model was also used to estimate changes in the propor-
tions infected according to cross-sectional data, i.e. small
sample size for TP development and poor follow-up to
test the model (dataset 3).
Matrix D, dataset 1
Transition probabilities developed from the Mali
baseline and year 1 data (Matrix D) were used to pre-
dict the longitudinal Ugandan dataset (dataset 1). This
was performed by way of testing model performance
when a dataset other than the Ugandan data are used
for calculation of the TPs. This addresses issues on
the generalizability of the MTP approach among en-
demic settings.
Results
We focus on the ability of the models to capture the ob-
served point prevalence values (and accompanying un-
certainty) within the 95 % PIs. Where the upper or
lower bounds of the 95 % CIs around the observed
values overlapped with the model predictions (or their
95 % PIs) only, the model was able to capture the uncer-
tainty in the data but not the point prevalence.
Predictions made on dataset 1
Table 3 shows all the predictions that were made for
dataset 1. The symbol next to the values highlights
predictions that were closest to the observed point
prevalence values and the values in bold highlight
predictions where observed point prevalence values fell
outside the 95 % PIs; in most cases however, the model
still captured some of the uncertainty around the
observed values (10 cases out of 13 shown in bold).
All of the predictions from each matrix captured the
observed point prevalence values within their PIs for the
low infection intensity prevalence category in each year
with the exception of matrix D (year 1 and marginally
for year 2) and for the prevalence of high intensity infec-
tions with the exception of matrix C (year 3), although
in both cases the 95 % PIs and the 95 % CIs overlapped.
When using the TPs derived from matrix A (the full
Ugandan dataset) to predict forward the reduction in
overall infection prevalence as well as in prevalence for
all infection intensity groups, the outputs matched the
observed data within the 95 % PIs for all time points
with the exception of the moderate intensity group and
the overall prevalence for year 2 (Fig. 3 and Table 3),
which indicated that the observed prevalence for each
infection intensity group was below the lower bound of
the prediction intervals of the estimated prevalence.
However, in both instances, the model captured the
95 % CIs of the observed values.
As with matrix A, matrices B (Additional file 1: Figure
S1a) and D (Fig. 4) also ‘highlighted’ year 2 for both
prevalence of moderate infection intensity and overall
prevalence as a year in which observed values fell below
95 % PIs (with matrix B capturing the upper 95 % CI
around the data, as with matrix A). Matrix C, however,
did not highlight any of the same time points identified
by the other matrices but instead, highlighted different
years in the moderate intensity, high intensity and
overall prevalence groups as time points in which
observed point prevalence levels were higher than pre-
dicted by the model (Additional file 1: Figure S1b).
Predictions made on dataset 2
Table 4 shows the predictions that were made for dataset
2 (see also Additional File 1: Figure S2). All 3 matrices
in this group indicated the same time point for the low
infection intensity group (year 3) and the overall preva-
lence group (year 1 and year 3) as performing below the
expected values, i.e. higher observed point prevalence
values than predicted (although matrix A also identified
year 2 for better programme performance than expected,
for overall infection prevalence). The same pattern in
predicted vs observed prevalence from dataset 1 by all
matrices was observed in the moderate infection inten-
sity group for all time points, with the exception of year
3 for matrix B, which mirrored matrix C estimates.
Matrices A and B performed similarly as in dataset 1 for
the high intensity group (i.e. all observations at each
time point were within the prediction intervals of the
model predictions) but matrix C indicated that the
observed prevalence values from years 1 and 2 were
marginally higher than expected. Matrix A was able to
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Table 3 Predicted mean prevalence by matrices A-D for dataset 1 (full Uganda cohort baseline year 0 – year 3)
Low intensity (predicted mean
prevalence and 95 % CI)
Moderate intensity (predicted
mean prevalence and 95 % CI)
High intensity (predicted mean
prevalence and 95 % CI)
Overall prevalence (predicted
mean prevalence and 95 % CI)
Matrix Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Observed
prevalence
dataset 1
0.134
(0.111–0.160)
0.099
(0.080–0.123)
0.102
(0.082–0.126)
0.075
(0.058–0.096)
0.021
(0.013–0.035)
0.033
(0.023–0.049)
0.035
(0.024–0.051)
0.016
(0.009–0.028)
0.020
(0.011–0.031)
0.244
(0.214–0.276)
0.137
(0.114–0.163)
0.154
(0.130–0.182)
Matrix A
Full dataset
0.142
(0.123–0.161)
0.108
(0.091–0.126)
0.095a
(0.077–0.113)
0.075a
(0.062–0.090)
0.044
(0.033–0.056)
0.033a
(0.023–0.045)
0.044
(0.033–0.055)
0.023
(0.015–0.032)
0.017a
(0.010–0.026)
0.261
(0.240–0.282)
0.175
(0.151–0.200)
0.144a
(0.119–0.171)
Matrix B
Uganda year
1 to year 2
0.135a
(0.112–0.158)
0.105
(0.086–0.126)
0.090
(0.072–0.109)
0.069
(0.051–0.090)
0.039
(0.028–0.051)
0.028
(0.019–0.038)
0.048
(0.031–0.066)
0.024
(0.015–0.036)
0.016
(0.009–0.024)
0.252a
(0.225–0.278)
0.168
(0.141–0.197)
0.133
(0.108–0.160)
Matrix C
3 selected districts
0.152
(0.122–0.183)
0.096a
(0.071–0.122)
0.082
(0.057–0.108)
0.045
(0.027–0.065)
0.016a
(0.008–0.027)
0.009
(0.003–0.017)
0.027
(0.013–0.043)
0.011a
(0.003–0.021)
0.008
(0.001–0.018)
0.223
(0.193–0.255)
0.123a
(0.093–0.156)
0.099
(0.069–0.132)
Matrix D
Mali full dataset
0.165
(0.141–0.190)
0.122
(0.100–0.146)
0.095a
(0.073– 0.117)
0.081
(0.062–0.101)
0.051
(0.037–0.068)
0.035
(0.023–0.049)
0.042a
(0.028–0.057)
0.021a
(0.012–0.032)
0.031
(0.007–0.021)
0.288
(0.264–0.312)
0.195
(0.164–0.226)
0.143
(0.113–0.175)
Bold = observed point prevalence values fell outside of the predicted boundaries
aClosest predictions to observed values
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Fig. 3 Matrix A predictions and dataset 1 observations. Matrix A was composed of transition probabilities derived from Uganda baseline and year 1
data and dataset 1 represents the full longitudinal Ugandan observations. These 4 plots show the predicted reduction in prevalence by Matrix A
(bands) vs observed (black points) in Uganda by overall prevalence group and by intensity group. The dotted line represents the pre-MDA prevalence
Fig. 4 Matrix D predictions and dataset 1 observations. Matrix D was composed of transition probabilities derived from Mali baseline and year 1 data
and dataset 1 represents the full longitudinal Ugandan observations. These 4 plots show the predicted reduction in prevalence by Matrix D (bands)
vs observed (black points) in Uganda by overall prevalence group and by intensity group. The dotted line represents the pre-MDA prevalence
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Table 4 Predicted mean prevalence by matrices A-C for dataset 2 (selected Ugandan districts)
Low intensity (predicted mean
prevalence and 95 % CI)
Moderate intensity (predicted
mean prevalence and 95 % CI)
High intensity (predicted mean
prevalence and 95 % CI)
Overall prevalence (predicted
mean prevalence and 95 % CI)
Matrix Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Observed
prevalence
dataset 2
0.158
(0.125–0.196)
0.105
(0.079–0.139)
0.143
(0.112–0.180)
0.100
(0.074–0.133)
0.020
(0.010–0.030)
0.045
(0.029–0.070)
0.055
(0.037–0.082)
0.030
(0.017–0.052)
0.018
(0.009–0.036)
0.313
(0.269–0.360)
0.155
(0.123–0.194)
0.205
(0.168–0.247)
Matrix A
Full dataset
0.152a
(0.133–0.172)
0.112
(0.095–0.130)
0.096
(0.078–0.115)
0.085a
(0.070–0.101)
0.048
(0.036–0.060)
0.034a
(0.024–0.046)
0.051
(0.039–0.063)
0.025
(0.017–0.035)
0.018a
(0.010–0.026)
0.289
(0.268–0.311)
0.185
(0.161–0.211)
0.148
(0.123–0.175)
Matrix B
Uganda year
1 to year 2
0.140
(0.115–0.166)
0.109a
(0.089–0.129)
0.092
(0.074–0.111)
0.078
(0.055–0.102)
0.042
(0.030–0.055)
0.029
(0.020–0.039)
0.055a
(0.035–0.077)
0.027a
(0.016–0.040)
0.017
(0.009–0.026)
0.272
(0.242–0.302)
0.178a
(0.149–0.208)
0.137
(0.111–0.165)
Matrix C
3 selected
districts
0.166
(0.132–0.199)
0.099
(0.075–0.124)
0.082
(0.057–0.108)
0.052
(0.031–0.075)
0.018a
(0.009–0.029)
0.010
(0.003–0.018)
0.031
(0.014–0.051)
0.012
(0.003–0.023)
0.008
(0.001–0.018)
0.249
(0.216–0.282)
0.129
(0.098–0.162)
0.100
(0.070–0.132)
Bold = observed point prevalence values fell outside of the predicted boundaries
a Closest predictions to observed values
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capture the uncertainty in all 12 observed values of data-
set 2, matrix B captured 10 out of 12 and matrix C cap-
tured 9 out 12.
Predictions made on dataset 3
Table 5 shows the predictions that were made for
dataset 3 (cross-sectional observed data). Figure 5
shows the output obtained from using the matrix A
model on dataset 3 and Additional File 1: Figure S3
shows the plots corresponding to applying matrices B
and C on dataset 3.
All data points in the low intensity of infection preva-
lence group were estimated accurately by each matrix,
where both the observed point prevalence values as well
as their 95 % CIs were captured by the model. As with
dataset 1, matrices A and B produced similar outputs,
with the observed data points and their 95 % CIs
predicted by the models, with the exception of year 3, in
moderate intensity, high intensity and overall prevalence
groups. For matrix C, other than the low infection inten-
sity group, the observed prevalence levels in all of the
other infection intensity groups in all years were greater
than the predicted range.
Predictions made on dataset 4
Figure 6 and Table 6 show the model outputs when
Ugandan TPs were used to estimate changes in the
longitudinal data from Mali. The results show that the
model predictions match the changes in prevalence
closely, with only year 2 observations from the low and
high infection intensity groups falling outside of the pre-
diction intervals, yet capturing the uncertainty around
the data. The low intensity year 2 prediction shows an
increase in prevalence, but inspection of the high inten-
sity group shows that this may be due to individuals
moving from the higher infection intensity groups to the
low intensity and the non-infected group. Additional File
1: Figure S4 also shows the output obtained when apply-
ing Matrix D to dataset 4, where all data points were
captured by the model with the exception of year 2 in
the low intensity group. In all years however, matrix D
captured the 95 % CIs of all observed data points.
Discussion
The primary aim of this study was to develop a simple
quantitative tool to help programme managers to moni-
tor and evaluate the ongoing progress of their schisto-
somiasis disease control interventions and whether they
are meeting their targets. For this, we parameterized and
validated Markov models using an extensive longitudinal
dataset of S. mansoni infection in Ugandan children
treated yearly with PZQ. Additionally, in order to test
the robustness of the model predictions in a completely
different setting, we compared model predictions against
data from comparable school-aged children from the na-
tional control programme in Mali. Our focus was on the
ability of the models to capture the observed point
prevalence values, as a conservative approach to model
assessment. It is anticipated that programme managers
will be able to use their own baseline and year 1 data to
predict changes in infection prevalence in subsequent
years of the same programme, as this is the scenario
where the model performed best.
Our study therefore demonstrated that this Markov
modelling approach is useful when making (relatively
short-term) predictions on infection trends with large
datasets from which a subset has been used to
parameterize the model (as seen by matrix A vs dataset
1 and matrix D vs dataset 4). Additionally, it is useful
when completely independent data from another coun-
try have been used to parameterize the model and when
predicting cross-sectional data. These results are par-
ticularly noteworthy since the vast majority of sentinel
site survey data tend to be cross-sectional in design
given inherent logistical and financial advantages. Matri-
ces A and B performed similarly (with matrix A predict-
ing changes in prevalence correctly within the 95 % PI
range at more follow-up times in each infection intensity
group than any other matrix variant), showing that the
models performed similarly, whether TPs developed
from baseline to year 1 data (matrix A) or from year 1
to year 2 (matrix B) were used to parameterize the
model. It is important to test the performance of the
model on a completely different country as this is 1
scenario for which a programme manager may use this
model, and for these reasons data from Mali (dataset 4)
were used to both separately test the model with Ugandan
TPs (matrix A) and parameterize the model (baseline and
year 1 data for matrix D). The model was able to predict a
large majority of data points within the estimated 95 %
PIs, in both cases: matrix A predicted all but 2 data points
within the 95 % PIs (but captured the 95 % CIs around the
data) for Mali dataset 4, and matrix D performed similarly
to matrices A and B when predicting dataset 1. Con-
versely, matrix C (using data from selected districts in
Uganda) performed least well, with only 16 of the 36
estimates in this study capturing the observed point
prevalence values within the 95 % PIs. However, it is not
possible to determine how the trends would continue
without further data; therefore, this study is limited to the
data we had available.
We conclude that, in its current form, the model is a
useful additional tool for programme managers, provided
they have the data available for the parameterisation of the
model to the local setting, and is particularly useful for the
interpretation of data from low and high infection inten-
sity areas where all of the models performed best. This is
ideal for programmes preparing to move from control of
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Table 5 Predicted mean prevalence by matrices A-C for dataset 3 (cross-sectional Ugandan data)
Low intensity (predicted mean
prevalence and 95 % CI)
Moderate intensity (predicted mean
prevalence and 95 % CI)
High intensity (predicted mean
prevalence and 95 % CI)
Overall prevalence (predicted
mean prevalence and 95 % CI)
Matrix Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Observed
prevalence
dataset 3
0.150
(0.139–0.161)
0.122
(0.112–0.132)
0.104
(0.094–0.115)
0.085
(0.077–0.094)
0.051
(0.044–0.053)
0.061
(0.053–0.070)
0.059
(0.052–0.070)
0.032
(0.028–0.038)
0.054
(0.048–0.062)
0.294
(0.280–0.308)
0.205
(0.193–0.218)
0.219
(0.205–0.233)
Matrix A
Full dataset
0.149a
(0.130–0.168)
0.111a
(0.093–0.128)
0.095a
(0.078–0.114)
0.082a
(0.068–0.097)
0.047a
(0.035–0.059)
0.034
(0.024–0.045)
0.049
(0.037–0.061)
0.024
(0.016–0.034)
0.017
(0.010–0.026)
0.280a
(0.259–0.301)
0.182a
(0.157–0.207)
0.147
(0.121–0.173)
Matrix B
Uganda year
1 to year 2
0138
(0.114–0.163)
0.108
(0.088–0.128)
0.091
(0.073–0.110)
0.075
(0.053–0.098)
0.041
(0.029–0.054)
0.028
(0.019–0.039)
0.052a
(0.033–0.073)
0.026a
(0.016–0.039)
0.017
(0.009–0.025)
0.265
(0.235–0.295)
0.174
(0.146–0.205)
0.136
(0.110–0.163)
Matrix C
3 selected districts
0.160
(0.128–0.193)
0.098
(0.074–0.123)
0.082
(0.057–0.108)
0.050
(0.029–0.072)
0.017
(0.008–0.029)
0.009
(0.003–0.018)
0.030
(0.014–0.049)
0.011
(0.003–0.022)
0.008
(0.001–0.018)
0.240
(0.208–0.273)
0.127
(0.096–0.159)
0.100
(0.070–0.131)
Bold = observed point prevalence values fell outside of the predicted boundaries
a Closest predictions to observed values
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morbidity to interruption of transmission and elimination
of infection (more feasible in low infection intensity areas)
or to elimination of schistosomiasis as a public health
problem (more severe in high infection intensity areas).
Availability of longitudinal follow-up data is not essential,
provided the sample size is large (as in this study) for
cross-sectional annual data; however, longitudinal data are
required to calculate the TPs. The use of data from Mali
for parameterization (matrix D) illustrated that the model
could, with some caution, be considered useful for
predicting prevalence changes in Uganda, but more
data would be required from other countries to test
this further.
These models are aimed to be a tool to aid decisions
and stimulate further investigation when needed rather
than be used as a precise prediction of likely impact.
Therefore, it is hoped that this heuristic technique may
be useful for programme managers as a quick and sim-
ple means of assessing the progress of programmes.
However, as seen by the results concerning dataset 4
(Mali longitudinal cohort), it is important to interpret
the data for all 4 infection intensity groups together,
since a large observed increase in the low infection
intensity group compared to model outputs, may likely
be linked to a corresponding decrease in the proportion
of the heavier infection intensity groups. The precise
change in infection patterns following treatment will de-
pend on a multitude of factors related to programmatic
design and performance. These will include therapeutic
coverage and treatment adherence, which in turn will be
related to other programmatic variables, such as the per-
formance of the drug distribution teams, the accuracy of
Fig. 5 Matrix A (full Ugandan baseline and year 1 transition probabilities) predictions and dataset 3. Dataset 3 represents cross-sectional Uganda
observations. These 4 plots show the predicted reduction in prevalence by Matrix A (bands) vs cross-sectional observed (black points) in Uganda
by overall prevalence group and by intensity group. The dotted line represents the pre-MDA prevalence
Table 6 Predicted mean prevalence by matrix A for dataset 4 (longitudinal Mali data)
Low intensity (predicted
mean prevalence and 95 % CI)
Moderate intensity (predicted
mean prevalence and 95 % CI)
High intensity (predicted
mean prevalence and 95 % CI)
Overall prevalence (predicted
mean prevalence and 95 % CI)
Matrix Year 1 Year 2 Year 1 Year 2 Year 1 Year 2 Year 1 Year 2
Observed prevalence
dataset 4
0.113
(0.094–0.135)
0.122
(0.102–0.145)
0.052
(0.040–0.069)
0.036
(0.025–0.050)
0.023
(0.015–0.036)
0.008
(0.004–0.016)
0.188
(0.164–0.215)
0.165
(0.142–0.191)
Matrix A
Full dataset
0.112
(0.095–0.129)
0.096
(0.079–0.115)
0.049
(0.039–0.059)
0.035
(0.025–0.046)
0.027
(0.020–0.035)
0.018
(0.011–0.027)
0.188
(0.169–0.207)
0.149
(0.126–0.174)
Bold = observed point prevalence values fell outside of the predicted boundaries
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census data, and the effectiveness of social mobilization
techniques, among others. Identifying the respective im-
pact of each of these factors is beyond the scope of this
paper.
Despite its advantages, the limitations of the Markov
approach must be understood if it is to constitute a use-
ful tool by programme managers. The model employed
in this study is referred to as a time-homogenous Mar-
kov process [28], which assumes that the TPs remain
constant through time. It is also assumed that they are
invariant with respect to setting (endemicity, geographic
location etc.) and host age group. This is not likely to
hold for long-term projections as interventions (in this
case MDA) are likely to have an impact on the transmis-
sion environment. For these reasons, such models may
indicate ‘abnormalities’ in the observed datasets as a
result of inevitable or expected changes over time, there-
fore the usefulness of the approach resides in its value as
an additional tool for monitoring and evaluation rather
than the definitive tool for this purpose. The data used
to validate and test the models are primarily from
school-aged children since most schistosomiasis inter-
ventions focus on this age group, who tend to harbour
the highest burden of infection [29–35]. Therefore, the
models do not consider the broader impact of MDA on
the entire community via the indirect (herd) effects on
transmission that result from reducing the force of
infection [13]. Moreover, the method also implies that
the same intervention is used each year using the same
treatment schedule, not accounting for complementary
interventions that may be implemented, such as those
relating to sanitation or education, increase in public
awareness that may accompany the progression of a
control programme, or changes in the frequency and/or
coverage of MDA. The model is based on a closed
system and, therefore, assumes no population migration
or extraneous introduction of new infections. This is an
important limitation for mobile communities that
may comprise so-called super-spreading individuals
(such as fishermen or bicycle washers) who contribute
disproportionately to community-wide transmission
and who may be more likely to miss treatment. How-
ever, this is also a general limitation of most helminth
transmission models, which rarely consider the spatial
aspects of transmission.
With these limitations in mind, this study demon-
strates that using constant TPs from the same dataset
or from different datasets provides a satisfactory pre-
diction of data (and their uncertainty) on the overall
prevalence and the prevalence of high, moderate and
light infections for up to 3 follow-up years. This
method could also be extended to S. haematobium,
adapting the model to the different WHO intensity
classes for this species (defined as 1–50 eggs/10 ml of
Fig. 6 Matrix A (Uganda baseline and year 1 transition probabilities) predictions and dataset 4. Dataset 4 represents full longitudinal Mali
observations. These 4 plots show the predicted reduction in prevalence by Matrix A (bands) vs observed (black points) in Mali by overall
prevalence group and by intensity group. The dotted line represents the pre-MDA prevalence
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urine as light intensity and > 50 eggs/10 ml of urine
as heavy intensity, with no moderate intensity group)
[9, 19] as well as to S. japonicum. In this case, the
transmission dynamics among multiple definitive
hosts would potentially pose less of a problem to this
modelling approach when compared to other models
that do not take into account the zoonotic reservoir,
as the TPs calculated from the initial data would in-
clude all of the transmission-related processes occur-
ring between the 2 time points [36–38]. This study
could also be expanded further by comparing differ-
ent TPs obtained from other datasets. In addition, the
models could be adapted to make longer-term predic-
tions (since the present study is focussed on short-
term changes of 1–3 years post-baseline due to the
stationary TP limitation), using datasets spanning
longer periods and incorporating MDA coverage
information. These extensions could, in principle, be
captured using multiple TPs based on existing data of
varying treatment coverage, or the possibility of hav-
ing dynamic TPs that change with time or are simply
updated as new data become available (developing
new TPs from the more recent followed cohort). The
use of year 1 to year 2 TPs in this study illustrated
the potential for updating TPs as the programme pro-
gresses to estimate changes in subsequent years. This
would overcome the constraints imposed by using
baseline and year 1 data only, for projecting over long
running programmes.
Conclusions
We developed and refined a Markov model to capture
changes in the prevalence of infection intensity categor-
ies for S. mansoni infection over multiple rounds of
MDA with PZQ. We parameterized our model using 2-
year (2 consecutive time points) longitudinal data from
Uganda and from Mali, using it to make longer-term
projections against different variations of the datasets.
The results from this study show that this is not only a
promising instrument for programmes in their early
years of implementation as a complementary M&E tool,
but also a useful quantitative approach for making
short-term projections of prevalence trends under inter-
ventions. With the ambitious WHO 2020 goals on the
horizon, there is a need to look beyond maintaining
control of schistosomiasis and shift focus to eliminat-
ing this debilitating disease. The global research com-
munity needs to develop practical tools to help
programmes to achieve these goals. The Markov
model has already produced encouraging results with
existing programmatic data. With the push towards
the elimination of schistosomiasis as a public health
problem by 2020, these findings come at a key time
in the field of NTD modelling for programme
managers and policy makers.
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